We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DAKT:NASDAQDaktronics, Inc. Analysis

Data as of 2026-06-13 - not real-time

$20.30

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Daktronics is trading near its 20‑day simple moving average, which sits just above the 50‑day SMA, indicating a modest short‑term bias. The RSI hovers around the mid‑50s, suggesting the stock is neither overbought nor oversold, while the MACD histogram has turned positive, giving a bullish signal despite the overall neutral trend. Volume is on an upward trajectory, supporting the technical optimism. Fundamentally, revenue is expanding at a healthy double‑digit pace and free cash flow yields are attractive, with cash generation comfortably covering the modest debt load. The DCF model places fair value near $39, implying more than 50% upside from the current price. Analyst sentiment is strongly positive, reflected in a “strong buy” consensus and a median price target above $30. Beta is elevated at roughly 1.6 and 30‑day volatility exceeds 30%, pointing to heightened price swings. Nonetheless, the balance sheet is solid, with ample cash and minimal leverage. The combination of growth momentum, sizable valuation upside, and strong cash flow positions DAKT as an appealing opportunity for investors willing to tolerate higher volatility.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near immediate support level
  • Bullish MACD histogram
  • Increasing trading volume

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong revenue growth and free cash flow generation
  • Valuation upside exceeding 50% versus DCF fair value
  • Analyst consensus of strong buy

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Sustainable growth prospects across diversified display segments
  • Robust balance sheet with low debt and high cash
  • Undervalued relative to intrinsic value and industry peers

Key Metrics & Analysis

Financial Health

Revenue Growth21.60%
Profit Margin3.43%
P/E Ratio36.9
ROE9.73%
ROA7.18%
Debt/Equity3.76
P/B Ratio3.3
Op. Cash Flow$77.2M
Free Cash Flow$55.3M
Industry P/E36.8

Technical Analysis

TrendNeutral
RSI53.7
Support$18.84
Resistance$21.86
MA 20$19.85
MA 50$19.75
MA 200$20.55
MACDBullish
VolumeIncreasing
Fear & Greed Index89.86

Valuation

Fair Value$38.93
Target Price$30.67
Upside/Downside51.07%
GradeUndervalued
TypeGrowth

Risk Assessment

Beta1.58
Volatility39.49%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.